Established by Johnson & Johnson, the Dr. Paul Janssen Award for Biomedical Research honours the founder of Janssen Pharmaceutica. The award salutes the most passionate and creative scientists in basic or clinical research, whose scientific achievements have made, or have strong potential to make, a measurable impact on human health. Professors Maini and Feldmann will be presented with their award and prize at events in New York and Beerse, Belgium in September.
Solomon Snyder, Ph.D., Distinguished Service Professor of Neuroscience, Pharmacology and Psychiatry, Johns Hopkins School of Medicine and Chairman, Janssen Award Selection Committee, said: The work of Feldmann and Maini exemplifies the bench-to-bedside approach that Paul Janssens contributions epitomized. It is extremely rare for researchers to identify a molecular messenger in test tube studies, demonstrate its physiologic relevance in animals and themselves carry these efforts forward to a successful clinical demonstration. Feldmann and Maini did all of this, leading to therapeutic agents of inestimable, lifesaving importance.
The work of Feldmann and Maini has dramatically transformed the treatment of chronic inflammatory conditions and given millions of people new hope, said Paul Stoffels, M.D., Company Group Chairman, Research & Development, Pharmaceuticals, Johnson & Johnson. The passion with which these two scientists have driven forward translational research reflects the leadership and innovation that defined Dr. Paul. Johnson & Johnson is delighted to honor them with the Dr. Paul Janssen Award for Biomedical Research.
In addition to winning the 2008 Dr. Paul Janssen Award for Biomedical Research, Professors Feldmann and Maini have been widely honored for their work. They have received various prizes including the Albert Lasker Clinical Medical Research Award in 2003 and the
|Contact: Laura Gallagher|
Imperial College London